Name: Noven Pharmaceuticals Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Noven Pharmaceuticals Inc.

Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Asenapine maleate transdermal patch: Phase III started

Hisamitsu Pharmaceutical Co. Inc sales and marketing update

Minivelle regulatory update

Noven, Novartis deal

Hisamitsu neurology, inflammation, endocrine/metabolic news

HP-3070: Phase I started

Endo, Hisamitsu, Teikoku Seiyaku, TWi Pharmaceuticals neurology news